Resilient Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Resilient Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,751 sponsors by registered trial count).
Resilient Pharmaceuticals: 17 sponsored US clinical trials, none currently recruiting.
Resilient Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 2 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage).
Top-decile sponsor footprint
Resilient Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study of Midomafetamine in Healthy Adults
NCT07584720
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
NCT03606538
Food Effects on Bioavailability of MDMA in Healthy Volunteers
NCT05147402
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
NCT04784143
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
NCT04714359
Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD
NCT05066282
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)
NCT04077437
Evaluation of MDMA on Startle Response
NCT03181763
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
NCT02876172
Correlates of Anxiety Associated With a Life-threatening Illness
NCT02954562
MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
NCT02427568
Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
NCT02008396
Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD
NCT02102802
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
NCT01793610
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers
NCT01404754
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
NCT01458327
Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder
NCT01211405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 6 |
| Phase 3 | 2 |
How the Resilient Pharmaceuticals early-phase archive is shaped
17 indexed studies, none listed as recruiting (0% open); 14 completed (82%).
Phase mix: 2 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Therapeutic area indexing for this sponsor is limited in the public registry.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.